In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα

Abstract The interaction of platelet GPIbα with von Willebrand factor (VWF) is essential to initiate platelet adhesion and thrombosis, particularly under high shear stress conditions. However, no drug targeting GPIbα has been developed for clinical practice. Here we characterized anfibatide, a GPIbα...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benjamin Xiaoyi Li, Xiangrong Dai, Xiaohong Ruby Xu, Reheman Adili, Miguel Antonio Dias Neves, Xi Lei, Chuanbin Shen, Guangheng Zhu, Yiming Wang, Hui Zhou, Yan Hou, Tiffany Ni, Yfke Pasman, Zhongqiang Yang, Fang Qian, Yanan Zhao, Yongxiang Gao, Jing Liu, Maikun Teng, Alexandra H. Marshall, Eric G. Cerenzia, Mandy Lokyee Li, Heyu Ni
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2f1cc945ff084274a10fe99842cf9bb1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα

Ejemplares similares